- Home
- LRMR vs ETO Comparison
LRMR vs ETO Comparison
Compare LRMR & ETO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LRMR | ETO |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.8M | 518.5M |
| IPO Year | 2014 | 2004 |
Fundamental Metrics
Financial Performance| Metric | LRMR | ETO |
|---|---|---|
| Price | $3.06 | $30.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $14.40 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 16.1K |
| Earning Date | 11-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.72 | $25.68 |
| 52 Week High | $6.42 | $32.35 |
Technical Indicators
Market Signals| Indicator | LRMR | ETO |
|---|---|---|
| Relative Strength Index (RSI) | 33.64 | 39.07 |
| Support Level | $3.02 | $29.57 |
| Resistance Level | $3.76 | $30.92 |
| Average True Range (ATR) | 0.20 | 0.55 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 15.36 | 28.47 |
Price Performance
Historical ComparisonAbout LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About ETO Eaton Vance Tax-Advantage Global Dividend Opp
Eaton Vance Tax-advtgd Global Divid Oppo is a diversified, closed-end management investment company. Its investment objective is to provide a high level of after-tax total return consisting of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. The portfolio of investments consists of capital markets, chemicals, diversified, beverages, banks, electric utilities, oil, gas, and consumable fuels, personal products, and other areas.